Impact of a medication therapy management service offered to patients in treatment of breast cancer
AUTOR(ES)
Amaral, Pedro Augusto do, Mendonça, Simone de Araújo Medina, Oliveira, Djenane Ramalho de, Peloso, Leonardo José, Pedroso, Reginaldo dos Santos, Ribeiro, Maria Ângela
FONTE
Braz. J. Pharm. Sci.
DATA DE PUBLICAÇÃO
26/07/2018
RESUMO
ABSTRACT Cancer has high morbidity and mortality rates related to medication use and produce a costly impact in health care. Thus, patients require constant monitoring and proper coordination of care between different professionals. This study aimed to evaluate the impact generated by a Medication Therapy Management service (MTM) offered to patients with breast cancer in use of polypharmacy. Observational, exploratory, descriptive and retrospective study of a MTM service that included 93 patients. Sociodemographic and clinical data related to pharmacotherapy and the processes associated with the systematization of the service were collected and analyzed. Patients were followed-up by the MTM service on average for 18 months (±4.31) and 185 drug-related problems (DRP) were identified, an average of two DRP per patient. Of these DRP, 48.11% were resolved and 49.73% were in the resolution process. The most common DRP were in the categories of Indication (37.84%), followed by Safety (23.78%). The safety category showed the highest resolution rate (59.09%). The study revealed an increased risk of DRP for patients with three or more comorbidities and using 5 or more medications. The process of systematization of a MTM service in oncology was associated with positive outcomes.
Documentos Relacionados
- Treatment of patients with immunodeficiency: Medication, gene therapy, and transplantation
- Breast Cancer Therapy Annual – today's drug treatment of cancer?
- Impact of breast magnetic resonance imaging on the locoregional staging and management of breast cancer
- Clinical practice guidelines for the care and treatment of breast cancer: the management of chronic pain in patients with breast cancer (summary of the 2001 update)
- Hypofractionated and hyper-hypofractionated radiation therapy in postoperative breast cancer treatment